SOURCE-LINKED STUDY SUMMARY
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial.
Abstract summarizedQuality not appraised
- What was studied
- This exploratory post-hoc analysis evaluated thigh muscle volume and fat infiltration during tirzepatide treatment.
- Who / model studied
- The analysis included 246 insulin-naive adults with type 2 diabetes who completed valid MRI scans at week 52.
- Studied dose & schedule
- Participants received tirzepatide 5, 10, or 15 mg subcutaneously once weekly, or titrated insulin degludec daily, for 52 weeks.
- What the study found
- Pooled tirzepatide reduced muscle volume by 0.64 L and muscle fat infiltration by 0.36 percentage points. Volume loss matched weight-loss-based population estimates, while fat infiltration improved more than estimated.
- Limitations & context
- This was exploratory, post-hoc, and limited to MRI-substudy participants with valid week-52 scans; the external comparison used modeled UK Biobank estimates.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s2213-8587(25)00027-0